CagriSema REDEFINE 9: what the lower-dose results tell us
New results explore two lower doses of investigational CagriSema. The study supports comparison with placebo, but cannot establish which dose is better.
Read the story ↗Original explanations of obesity research and medicine developments, written for UK readers. We separate study results, regulatory authorisation and NHS funding — because each answers a different question.
Explore upcoming medicines ↗New results explore two lower doses of investigational CagriSema. The study supports comparison with placebo, but cannot establish which dose is better.
Read the story ↗Recent company reports describe further phase 3 findings. Retatrutide remains investigational, and the population and comparator matter when interpreting its results.
Read the story ↗Orforglipron, branded Foundayo, received UK authorisation in August 2026. A tablet changes the treatment routine, but assessment, monitoring and access decisions still matter.
Read the story ↗Oral Wegovy is licensed and has launched in the UK. NHS England’s guidance explains why that does not make tablets routinely available through every NHS service.
Read the story ↗WHO’s first guideline on GLP-1 therapies for adult obesity makes conditional recommendations and asks health systems to address affordability, continuity and unequal access.
Read the story ↗A percentage alone cannot describe a clinical trial. Check the source, participants, comparator, analysis and harms before deciding what a result might mean.
Read the story ↗